Across TCGA pan-cancer cohorts, SKOR2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SKOR2 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SKOR2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SKOR2 expression acts as an unfavorable survival marker.
LUSC and UCEC are the cancer types where SKOR2 Mutation most reproducibly stratifies survival.